Sagimet Biosciences, Inc. Class A share price logo

Sagimet Biosciences, Inc. Class A

NASDAQ: SGMT

Small Cap

$9.58

-0.37

(-3.72%)

Live

as on

Sagimet Biosciences, Inc. Class A Stock Performance

as on October 24, 2026 at 6:27 am IST

  • Day's Low

    Day's High

    $9.49
    $9.93
    downward going graph

    0.94%

    Downside

    3.65%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $4.50
    $11.45
    downward going graph

    53.03%

    Downside

    19.51%

    Upside

    downward going graph

Sagimet Biosciences, Inc. Class A share price movements today

Previous Close
$9.95
Open
$9.82
Volume
439.2K
Market Cap
$708.4M
Day's Low - High
$9.49 - $9.93
52 Week Low - High
$4.50 - $11.45

Sagimet Biosciences, Inc. Class A Historical Returns

1 Month Return
-4.51 %
3 Month Return
+ 41.94 %
1 Year Return
+ 35.74 %
3 Year Return
+ 119.16 %
5 Year Return
0 %

Sagimet Biosciences, Inc. Class A Stock Fundamentals & Key Indicators

Check Sagimet Biosciences, Inc. Class A market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$708.4M

EPS (TTM)

-1.28

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-7.8

Industry PE ratio

-7.12

PEG Ratio

-0.21

EBITDA

-49.7M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-31.96%

Sagimet Biosciences, Inc. Class A vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Sagimet Biosciences, Inc. Class A with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$708.4MNA-7.800.00%0.00%
Neutral$98.1B-37.95%-30.80-12.57%0.00%
StrongBuy$44.0BNA27.4787.82%0.00%
StrongBuy$132.9B191.61%30.2886.04%0.00%
Buy$83.1B43.11%19.2484.86%0.46%

Stock Returns calculator for Sagimet Biosciences, Inc. Class A Stock including INR - Dollar returns

The Sagimet Biosciences, Inc. Class A stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Sagimet Biosciences, Inc. Class A investment value today

Current value as on today

₹1,41,358

Returns

₹41,358

(+41.36%)

Returns from Sagimet Biosciences, Inc. Class A Stock

₹30,696 (+30.7%)

Dollar Impact

₹10,662 (+10.66%)

Analyst Recommendation on Sagimet Biosciences, Inc. Class A Stock

Based on 6 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 6 analysts, 100% of analysts recommend a 'BUY' rating for Sagimet Biosciences, Inc. Class A. Average target price of $27.91

Sagimet Biosciences, Inc. Class A Share Price Target

Get share price movements and forecasts by analysts on Sagimet Biosciences, Inc. Class A.

What analysts predicted

65.68%UPSIDE

Target Price

$27.91

Current Price

$9.58

Analyzed by

6 Analysts

High

$56

Target

$27.91

Low

$26

Sagimet Biosciences, Inc. Class A target price $27.91, a slight upside of 65.68% compared to current price of $9.58. According to 6 analysts rating.

Indian Investors' Interest in Sagimet Biosciences, Inc. Class A Stock

Search interest for Sagimet Biosciences, Inc. Class A Stock has decreased by -21% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-21% versus previous 30 day period

Sagimet Biosciences, Inc. Class A Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
-
-
-
-
Operating Income
-8
-10
-16
-18
-19
-11
-14
-10
-11
-15
EBITDA
2
-8
-14
-16
-18
-10
-12
-12
-10
-13
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
8
-
-
-
-
-
-
-
-
-
Income Before Tax
-6
-8
-14
-16
-18
-10
-12
-9
-10
-13
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-6
-8
-14
-16
-18
-10
-12
-9
-10
-13
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Sagimet Biosciences, Inc. Class A Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
2
-
-
Gross Profit
0
-
-
-
2
-
-
Operating Income
-14
-11
-23
-31
-30
-54
-56
EBITDA
-14
-11
-24
-30
-27
-45
-51
Interest Expense
0
-
-
-
-
-
-
Depreciation
0
0
-
0
-
-
-
Income Before Tax
-14
-11
-24
-30
-27
-45
-51
Income Tax Expense
-
-
-
-
-
-
-
Net Income
-14
-11
-24
-30
-27
-45
-51
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
100.00%
0.00%
0.00%

Sagimet Biosciences, Inc. Class A Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-6
-8
-14
-16
-18
-10
-12
-9
-10
-13
Operating Cash Flow
-6
-5
-19
-11
-14
-9
-10
-11
-8
-10
Investing Cash Flow
3
-75
0
9
3
-13
0
14
10
-24
Financing Cash Flow
104
0
-
-
-
0
0
-
-
339
Change in Cash
101
-80
-18
-1
-11
-22
-9
2
1
304

Sagimet Biosciences, Inc. Class A Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-14
-11
-24
-30
-27
-45
-51
Operating Cash Flow
-10
-10
-21
-24
-23
-42
-45
Investing Cash Flow
0
0
-
-32
12
-61
4
Financing Cash Flow
18
68
9
0
86
104
0
Change in Cash
7
58
-11
-56
74
0
-40

Global Institutional Holdings in Sagimet Biosciences, Inc. Class A

Check out the Institutions with significant holdings in Sagimet Biosciences, Inc. Class A.

Funds
Holdings
Vanguard
4.35%
Michael Rockefeller
4.27%
iShares
4.08%
Federated Hermes Equity Funds
2.96%
SPDR
2.09%

Sagimet Biosciences, Inc. Class A News & Key Events

  • img

    Today's Timeline - 30 September

    Wed, 03:55 PM

    -

    Sagimet prices 8.75M shares at $10.00 in underwritten offering, expecting gross proceeds of approximately $115M.

    Wed, 04:00 PM

    -

    Sagimet reports positive Phase 3 trial results for denifanstat in moderate to severe acne, reinforcing its clinical profile.

    Thu, 03:20 AM

    -

    Clear Street maintains buy rating and $28 price target on Sagimet after positive Phase 3 trial data.

Insights on Sagimet Biosciences, Inc. Class A

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, SGMT stock has moved up by 24.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 157.7% return, outperforming this stock by 38.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 671.9% return, outperforming this stock by 636.2%

About Sagimet Biosciences, Inc. Class A

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
OrganisationSagimet Biosciences, Inc. Class A
Headquarters155 Bovet Road, San Mateo, CA, 94402, US
IndustryBiotechnology
CEODavid Happel

Key Management of Sagimet Biosciences, Inc. Class A

Name

Title

Mr. Urs Greber Ph.D.

Co-Founder

Dr. Lucas Pelkmans Ph.D.

Co-Founder

Mr. Thierry Chauche

CFO & Principal Accounting Officer

Dr. Marie O'Farrell Ph.D.

Chief Scientific Officer

Mr. Robert D'Urso

Senior Vice President of New Products

Dr. Andreas Grauer M.D.

Chief Medical Officer

Mr. David A. Happel

CEO, President & Director

Ms. Elizabeth Rozek Esq., J.D.

Chief Legal & Administrative Officer

FAQs

What is Sagimet Biosciences, Inc. Class A share price today?

Sagimet Biosciences, Inc. Class A share price today is $9.58 as on . Sagimet Biosciences, Inc. Class A share today touched a day high of $9.93 and a low of $9.49.

What is the 52 week high and 52 week low for Sagimet Biosciences, Inc. Class A share?

Sagimet Biosciences, Inc. Class A share touched a 52 week high of $11.45 on and a 52 week low of $4.50 on . Sagimet Biosciences, Inc. Class A stock price today i.e. is trending at $9.58,which is 16.32% down from its 52 week high and 112.89% up from its 52 week low.

What is Sagimet Biosciences, Inc. Class A's market capitalisation today?

Sagimet Biosciences, Inc. Class A market capitalisation is $0.00T as on .

How to invest in Sagimet Biosciences, Inc. Class A Stock (SGMT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Sagimet Biosciences, Inc. Class A on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Sagimet Biosciences, Inc. Class A Stock (SGMT) from India?

Indian investors can start investing in Sagimet Biosciences, Inc. Class A (SGMT) shares with as little as ₹94.94000244140625 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Sagimet Biosciences, Inc. Class A stock (as per the Rupee-Dollar exchange rate as on ). Based on Sagimet Biosciences, Inc. Class A share’s latest price of $9.58 as on October 24, 2026 at 12:57 am IST, you will get 1.0438 shares of Sagimet Biosciences, Inc. Class A. Learn more about fractional shares .